Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)
China · Delayed Price · Currency is CNY 7.99
-0.15 (-1.84%)
Sep 11, 2026, 3:04 PM CST
SHE:300009 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 13,570 | 15,966 | 14,415 | 17,094 | 15,623 | 21,448 | |
Market Cap Growth | -23.41% | 10.76% | -15.68% | 9.42% | -27.16% | 7.00% |
Enterprise Value | 12,389 | 14,862 | 13,395 | 16,089 | 14,822 | 20,627 |
Last Close Price | 8.14 | 9.28 | 8.13 | 9.37 | 8.38 | 11.46 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.38 | 21.72 | 20.39 | 20.18 | 22.21 | 103.80 |
Forward PE | 17.32 | 14.16 | 14.16 | 17.47 | 21.27 | 35.62 |
PS Ratio | 5.53 | 6.03 | 5.68 | 5.97 | 6.70 | 9.89 |
PB Ratio | 3.08 | 3.37 | 3.35 | 4.35 | 4.59 | 7.39 |
P/TBV Ratio | 3.56 | 3.90 | 3.95 | 5.31 | 5.43 | 8.24 |
P/FCF Ratio | 19.91 | 21.68 | 25.37 | 22.56 | 69.55 | 46.53 |
P/OCF Ratio | 16.56 | 18.50 | 21.03 | 17.94 | 22.35 | 36.22 |
PEG Ratio | - | 0.79 | 0.79 | 0.92 | 0.32 | 1.15 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.05 | 5.62 | 5.28 | 5.61 | 6.36 | 9.51 |
EV/EBITDA Ratio | 13.95 | 16.24 | 15.38 | 16.20 | 17.73 | 30.48 |
EV/EBIT Ratio | 16.32 | 18.57 | 17.65 | 17.62 | 19.61 | 34.42 |
EV/FCF Ratio | 18.18 | 20.18 | 23.58 | 21.24 | 65.98 | 44.75 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.11 | 0.04 | 0.06 | 0.06 | 0.04 | 0.04 |
Debt / FCF Ratio | 0.14 | 0.05 | 0.10 | 0.08 | 0.15 | 0.06 |
Net Debt / Equity Ratio | -0.30 | -0.33 | -0.32 | -0.36 | -0.33 | -0.38 |
Net Debt / EBITDA Ratio | -1.51 | -1.69 | -1.60 | -1.41 | -1.36 | -1.63 |
Net Debt / FCF Ratio | -1.96 | -2.10 | -2.45 | -1.85 | -5.05 | -2.39 |
Asset Turnover | 0.49 | 0.50 | 0.50 | 0.62 | 0.59 | 0.61 |
Inventory Turnover | 2.18 | 2.40 | 2.18 | 2.81 | 2.62 | 2.59 |
Quick Ratio | 3.46 | 3.31 | 2.95 | 2.44 | 2.45 | 2.74 |
Current Ratio | 4.03 | 3.74 | 3.41 | 2.75 | 2.83 | 3.07 |
Return on Equity (ROE) | 16.67% | 16.54% | 17.39% | 23.41% | 23.40% | 6.98% |
Return on Assets (ROA) | 9.44% | 9.37% | 9.41% | 12.39% | 11.92% | 10.44% |
Return on Invested Capital (ROIC) | 21.52% | 23.55% | 24.86% | 35.50% | 32.85% | 21.45% |
Return on Capital Employed (ROCE) | 16.60% | 16.30% | 17.00% | 22.20% | 21.10% | 19.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.17% | 4.61% | 4.90% | 4.96% | 4.50% | 0.96% |
FCF Yield | 5.02% | 4.61% | 3.94% | 4.43% | 1.44% | 2.15% |
Dividend Yield | 2.98% | 2.69% | 3.07% | 2.67% | 2.99% | 1.74% |
Payout Ratio | 60.94% | 56.24% | 58.78% | 48.52% | 46.59% | 132.37% |
Buyback Yield / Dilution | 0.55% | 0.73% | -0.57% | -2.34% | -2.90% | 2.58% |
Total Shareholder Return | 3.52% | 3.43% | 2.51% | 0.33% | 0.09% | 4.33% |